A Study of Isoprinosine in Patients With Severe AIDS
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002295
- Lead Sponsor
- Newport Pharmaceuticals International
- Brief Summary
To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to:
Laboratory (immunologic defects):
* Comparison of total helper and suppressor T-cell numbers among the groups.
* Comparison of changes in natural killer cell activity.
* Comparison of other laboratory findings among the groups.
Clinical changes:
* Comparison of the frequency of opportunistic infections among the groups.
* Comparison of the frequency of the development of AIDS-related malignancies.
* Comparison of other clinical manifestations relative to severity and time of onset.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Newport Pharmaceuticals International Inc
🇺🇸Laguna Hills, California, United States
Newport Pharmaceuticals International Inc🇺🇸Laguna Hills, California, United States